{
    "clinical_study": {
        "@rank": "31844", 
        "arm_group": {
            "arm_group_label": "early staged non-small cell lung cancer", 
            "description": "patients diagnosed as early staged non-small cell lung cancer and received surgery in HunanPTH"
        }, 
        "biospec_descr": {
            "textblock": "3-4 ml whole blood was obtained and then centrifuged and stored at -20\u2103."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "In pre-clinical study, we found that serum thioredoxin reductase activity harbours huge\n      difference after any kind of treatments, so we hypothesis that serum activity of thioredoxin\n      reductase may be a warning markers in excised non-small lung cancers, serum activity of this\n      enzyme may elevated before CT scan"
        }, 
        "brief_title": "Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-small Cell Lung Cancer Stage I", 
            "Non-small Cell Lung Cancer Stage II", 
            "Non-small Cell Lung Cancer Stage IIIA"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a cooperative research project in Thoracic Surgery Department and Medical Oncology\n      department of Affiliated Cancer Hospital of xiangya School of Medicine Central South\n      University, and the State Key Laboratory for Natural Medicine and Biomimetic Drugs Perking\n      University. The primary objective is to measure the thioredoxin reductase activity in blood\n      in staged(\u2160~\u2162A) non-small lung cancers, to study the warning relapse ability of thioredoxin\n      reductase in blood. The secondary objective is to compare the warning relapse activity of\n      blood thioredoxin reductase activity with carcinoembryonic antigen (CEA) in subjects who\n      received surgery. Blood will be collected in subjects before surgery, 5 days after surgery,\n      and every 3 months after surgery till 2 years, then every 6 months till 3 years, or collect\n      blood till tumor relapse for the subjects at stage \u2160A and low risk \u2160B. Blood will be\n      collected before surgery, 5 days after surgery, before adjuvant chemotherapy, after 2\n      circles of all adjuvant chemotherapy, then every 3 months after adjuvant chemotherapy till 2\n      years, and every 6 months till 3 years, or collect blood till tumor relapse for the subjects\n      of high risk \u2160B~\u2162A, evaluation CT results every time collect blood samples."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically proven staged(\u2160~\u2162A) non-small cell lung cancer or CT scan shows\n             resectable lung mass, fast pathology proved non-small cell lung cancer\n\n          -  Receive surgery in Thoracic Oncology department Affiliated Cancer Hospital of xiangya\n             School of Medicine Central South University without contraindication of surgery\n\n          -  Tumor treatment naive\uff08except for surgery for cervical cancer and cutaneous squamous\n             cell carcinoma 5 years before\uff09\n\n          -  Signed informed consent to provide blood and tissue for study\n\n        Exclusion Criteria:\n\n          -  Patients received antitumor treatment before\n\n          -  Patients with contraindication of surgery or patients who need adjuvant chemotherapy\n             with contraindication of chemotherapy\n\n          -  Pregnant or breast feeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients diagnosed with resectable non-small lung cancer and received surgery in\n        Affiliated Cancer Hospital of xiangya School of Medicine Central South University,\n        HunanPTH"
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991418", 
            "org_study_id": "TR002", 
            "secondary_id": "EWSOTRILC"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "non-small cell lung cancer", 
            "thioredoxin reductase", 
            "carcina embryonic antigen"
        ], 
        "lastchanged_date": "June 1, 2014", 
        "location": {
            "contact": {
                "email": "yangnong0217@163.com", 
                "last_name": "Nong Yang, MD", 
                "phone": "+86 731 89762323"
            }, 
            "contact_backup": {
                "email": "zhouchunhua@hnszlyy.com", 
                "last_name": "Chunhua Zhou, MD", 
                "phone": "+86 731 89762321"
            }, 
            "facility": {
                "address": {
                    "city": "Changsha", 
                    "country": "China", 
                    "state": "Hunan", 
                    "zip": "410013"
                }, 
                "name": "Hunan Provincal Tumor Hospital"
            }, 
            "investigator": {
                "last_name": "Nong Yang, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Early Warning Study of Plasma Thioredoxin Reductase Activity in Non-small Cell Lung Cancers Received Surgery", 
        "overall_contact": {
            "email": "yangnong0217@163.com", 
            "last_name": "Nong Yang, MD", 
            "phone": "+86 731 89762323"
        }, 
        "overall_contact_backup": {
            "email": "zhouming243@gmail.com", 
            "last_name": "Ming Zhou, MD", 
            "phone": "+86 731 89762320"
        }, 
        "overall_official": {
            "affiliation": "Hunan Province Tumor Hospital", 
            "last_name": "Nong Yang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measure the thioredoxin reductase activity in blood at the setting time point, before surgery, 3-5 days after surgery, after every 3 months after surgery till 2 years, then every 6 months till 3 years, or collect blood till tumor relapse in patients at stage \u2160A and low risk \u2160B. Blood will be taken before surgery, 3-5 days after surgery, before adjuvant chemotherapy, after two cycles of adjuvant chemotherapy,  after every 3 months after adjuvant chemotherapy till 2 years, then every 6 months till 3 years, or collect blood till tumor relapse in patients at stage high risk \u2160B IIA IIB and IIIA.", 
            "measure": "Measure the thioredoxin reductase activity in blood", 
            "safety_issue": "Yes", 
            "time_frame": "blood should be taken before and 3-5 days after surgery, then every 3 months till 2 years, then every 6 month till 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991418"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hunan Province Tumor Hospital", 
            "investigator_full_name": "Nong Yang", 
            "investigator_title": "chief", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Measure the carcina embryonic antigen(CEA) level in blood at the setting time point, before surgery, 3-5 days after surgery, after every 3 months after surgery till 2 years, then every 6 months till 3 years, or collect blood till tumor relapse in patients at stage \u2160A and low risk \u2160B. Blood will be taken before surgery, 3-5 days after surgery, before adjuvant chemotherapy, after two cycles of adjuvant chemotherapy,  after every 3 months after adjuvant chemotherapy till 2 years, then every 6 months till 3 years, or collect blood till tumor relapse in patients at stage high risk \u2160B IIA IIB and IIIA.", 
            "measure": "Measure carcina embryonic antigen(CEA) level in blood", 
            "safety_issue": "Yes", 
            "time_frame": "blood should be taken before and 3-5 days after surgery, then every 3 months till 2 years, then every 6 month till 3 years"
        }, 
        "source": "Hunan Province Tumor Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hunan Province Tumor Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}